# PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)

> **NCT02702492** · PHASE1 · TERMINATED · sponsor: **Karyopharm Therapeutics Inc** · enrollment: 60 (actual)

## Conditions studied

- Solid Tumors
- NHL

## Interventions

- **DRUG:** KPT-9274
- **DRUG:** Niacin ER
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02702492
- **Lead sponsor:** Karyopharm Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06-08
- **Primary completion:** 2021-01-26
- **Final completion:** 2021-01-26
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** sponsor decision
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02702492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02702492, "PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT02702492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*